Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use

A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday.

...